Showing 7041-7050 of 8649 results for "".
- FDA Clears ViGeneron's IND for Novel mRNA Gene Therapy to Treat Stargardt Disease and Other Retinal Dystrophieshttps://modernod.com/news/fda-clears-vigenerons-ind-for-novel-mrna-trans-splicing-gene-therapy-vg801-to-treat-stargardt-disease-and-other-abca4-linked-retinal-dystrophies/2482585/ViGeneron announced that the FDA has cleared the investigational new drug (IND) application for the phase 1/2 study of VG801, a gene therapy candidate to treat Stargardt disease and other retinal dystrophies associated with mutations in the&n
- Eylea HD Phase 3 Trial Meets Primary Endpoint in Patients with RVOhttps://modernod.com/news/eylea-hd-phase-3-trial-meets-primary-endpoint-showing-improved-vision-with-extended-dosing-intervals-in-patients-with-rvo/2482583/Regeneron announced the primary endpoint was met in the phase 3 QUASAR trial investigating Eylea HD (aflibercept) injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions.
- Tenpoint and Visus Complete Mergerhttps://modernod.com/news/tenpoint-and-visus-complete-merger/2482576/Tenpoint Therapeutics and Visus Therapeutics announced the completion of their merger. “As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with Brimochol PF, a near-term therapeutic medicine for presbyopia
- Iantrek Publishes 12-Month Results for its Bio-Interventional Uveoscleral Outflow Technologyhttps://modernod.com/news/iantrek-announces-publication-highlighting-12-month-results-for-its-bio-interventional-uveoscleral-outflow-technology/2482574/Iantrek has announced 1-year results for the first 100 eyes enrolled in the CREST Registry, a real-world, prospective, observational study evaluating bio-interventional procedures in patients with open-angle glaucoma (OAG). The findings,
- The Centre for Eye and Vision Research and SCOPE Health Partner to Innovate Ocular Surface Disease Solutionshttps://modernod.com/news/the-centre-for-eye-and-vision-research-and-scope-health-partner-to-innovate-ocular-surface-disease-solutions/2482571/The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have signed a Memorandum of Understanding (MoU) to collaborate on technologies to treat dry eye disease and other ocular surface conditions. The partnership aims to address unmet needs in eye care by leveraging SCOPE&rs
- OneSight EssilorLuxottica Foundation Partners with WHO on SPECS 2030 Initiativehttps://modernod.com/news/onesight-essilorluxottica-foundation-partners-with-who-on-specs-2030-initiative-1/2482570/The OneSight EssilorLuxottica Foundation has announced a collaboration with the World Health Organization (WHO) as a global partner in the SPECS 2030 initiative. This strategic alliance is set to accelerate progress toward the world’s first global target for effective refractive error cover
- Galimedix Begins Phase 1 Clinical Trial of Oral GAL-101 for Neuroprotective Treatmenthttps://modernod.com/news/galimedix-therapeutics-begins-phase-1-clinical-trial-of-oral-gal-101-for-neuroprotective-treatment/2482565/Galimedix Therapeutics announced the first volunteers have been dosed in the company’s phase 1 study of oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses
- Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in Chinahttps://modernod.com/news/nicoxs-denali-phase-3-trial-of-ncx-470-fully-enrolled-in-china/2482561/Nicox announced that its Denali phase 3 trial evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension is now fully enrolled in China and screening has been closed. Completion of recruitment of patients in the
- FDA Clears Novoxel's Tixel for the Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/fda-clears-novoxels-tixel-for-the-treatment-of-meibomian-gland-dysfunction/2482559/Isreal-based Novoxel announced the the FDA clearance of its Tixel device for application of localized heat and pressure for patients with evaporative dry eye due to meibomian gland dysfunction (MGD). The Tixel systems use proprietary Thermo-Mechanical Actio
- NIH-Led Science Team Defines Elements of Cerebral Vision Impairmenthttps://modernod.com/news/nih-led-science-team-defines-elements-of-brain-based-leading-cause-of-childhood-vision-loss/2482557/Cerebral (or cortical) vision impairment (CVI) is a leading cause of childhood vision impairment in the United States and other industrialized nations, affecting at least 3% of primary school children. As vision is closely tied to learn